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Immunogenicity and allcrgcnicity studies in rodents show that cefotaxime and cefur-
oxime are less immunogenic than benzylpenicillin or the semisynthetic penicillins.
Cross-reactions of these antibiotics with benzylpenicilloyl-specific animal and human
IgE antibodies appear minimal. Some cross-reactivity at the level of cell-mediated
allergic reactions may, however, be expected.
Introduction
Allergic and immune reactions remain one of the major side-effects of /Wactam anti-
biotics. However, as experience with natural and semisynthetic penicillins has shown,
there may be variations in the incidence, the severity and also the clinical forms of
allergic reactions to /Mactam antibiotics according to their structure, chemical reac-
tivity, dosage and mode of administration. Therefore, the development of a new /J-
lactam antibiotic raises the following questions: (1) Is this new antibiotic potentially
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Flgort 1. Skie-chain structures and generic names of cephalosporins and some abbreviations.
•Abbreviations used: CEFOX, cefuroxime; CEPHALEX, cephalexin; CEPHOR, cephaloridine; CETAX,
cefoUiime; CEPHALOT, cephalothin; BPO, benzylpenicilloyl; BPO-FLYS, N'-formyl-W-benzylpenidlloyl-
L-lysine; BPNCO, benzylpenicilloic acid; BPN, benzylpenicillin; AMPIC, ampicillin; PLL, poly-L-lysine;
BGG, bovine gamma globulin; HSA, human serum albumin.
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sensitizing as the other drugs currently on the market? (2) Will this new penicillin or
cephalosporin cross-react with other already established /Mactam antibiotics and cor-
respondingly will it elicit allergic reactions in patients already hypersensitive to
penicillin?
This brief presentation aims to answer these questions as far as cefotaxime
(CETAX) and another cephalosporin of similar side-chain structure, cefuroxime
(CEFOX) are concerned (Figure 1).
Immunogenicity
The capacity of /Mactam antibiotics to evoke immune responses and to sensitize has
been classically linked, as for other sensitizing low-molecular weight chemicals, to their
capacity to form covalent bonds with soluble and membrane proteins. Accordingly,
chemical reactivity with various amino acids, peptides or proteins has sometimes been
taken as a measure of the expected immune reactivity. Indeed, aminolysis rate among
penicillins is variable and seems to correlate to some extent with the capacity to sensi-
tize rodents. While the reactivity of penicillins to form the major penicilloyl antigenic
determinant is well known, the corresponding immunochemistry of cephalosporins is
more complex and has been less extensively studied (Dewdney, 1977). Studies on the
chemical reactivity of cephalosporins with amines or proteins at various pH have sug-
gested that cephalosporoyl amide, the equivalent of the penicilloyl haptenic group is of
low stability and may decompose to more simple, e.g. penaldate, derivatives.
Table L Comparative immunogenicity of CEFOX-BGG conjugate, CEFOX, CETAX, CEPHOR
and penicillins
Immunization with
CEFOX-BGG
1 fig in Al(OH)j on
days 0, 21, 42, 63
CEFOX
1 mg in A1(OH)3 on
days 0, 21, 42, 63, 84
CEPHOR
1 mg in A1(OH)3 on
days 0, 21, 42, 63, 84
CETAX
1 mg in A1(OH)3 on
days 0, 21, 42, 63, 84
Benzylpenicillin (BPN)
Ampicillin (AMPI)
Serum tested
Serum from day
70
49
91
49
49
49
49
forPCA
Tested with
CEFOX-PLL
CEFOX-HSA
BPO-PLL
CEPHOR-PLL
CEFOX-PLL
CEPHOR-PLL
BPO-PLL
CEFOX-PLL
CEPHOR-PLL
BPO-PLL
CEFOX-PLL
CEPHOR-PL
BPO-PLL
CEFOX-PLL
CEPHOR-PL
BPO-PLL
BPO-PLL
AMPI-PLL
10/10
10/10
0/10
10/10
0/8
0/8
0/8
0/8
0/8
0/8
0/8
0/8
0/8
0/8
0/8
0/8
17/20
3/8
( > 1 : 1 0 000)
( > 1 : 1 0 000)
(1:10)
(1:400)
33
3
33
3
33
3
(1 :10)
(1 :10)
(1 :10)
(1:200)
(1:20)
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Cephalosporin determinants having undergone such transformation retain the side-
chain (Kj) but lack the dihydrothiazine ring (Hamilton-Miller, Newton & Abraham,
1970; Steinberger & Wiedermann, 1970).
Upon repeated injection of guinea pigs with penicillins either with various adjuvants
or without adjuvant (thus mimicking therapeutic administration) large variations in
the capacity to sensitize have been observed. While benzylpenicillin is regularly sensitiz-
ing producing antibodies of benzylpenicilloyl specificity, antibody production to, e.g.
ampicillin, appears much less constant. We have been unable under experimental con-
ditions to achieve sensitization either by cefotaxime or cefuroxime. However, when
preformed protein conjugates are used for immunization high grade sensitization to the
cephalosporins is regularly achieved with high titres of antibodies as detected by passive
cutaneous anaphylaxis (Tables I and II). As studied in some detail in the penicillin
Table n. Active and passive anaphylactic reactions in animals immunized with CEPHOX-BGG
Guinea
no.
CEFOXt
Pig*
1:10
CEFOX-
HSA
1:10000
PCA elicited
BPO-
FLYS
1:10
by
BPO
1:10
BPNCO
1:10
BPO-
PLL
1:10
Active shock
CEFOX 25 mg
l.V.
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
434J
490
706
379
706
542
510
672
618
370
78
103
160
314
298
314
356
356
177
490
111
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
death
death
death
severe shock
death
not done
death
death
death
severe shock
T e n guinea pigs immunized with 1 p.% CEFOX-BGG in A](OH)3; PCA with serum from day 105, eli-
citation of shock on day 109.
f EUcitor doses were 25 mg for monovalent compounds and 1 /jmol hapten for conjugates. The ratios given
indicate serum dilutions.
{Blue reaction in mm2.
system, antibodies produced against the penicilloyl antigenic determinant may be di-
vided into three categories: (a) those specific for the side-chain; (b) those specific for the
thiazolidine nucleus; (c) those specific for the whole hapten. As will be discussed later, it
appears that antibodies raised by cefuroxime-protein conjugates are to a large extent
specific for the cefuroxime side-chain as very little cross-reactivity with other penicillins
and/or cephalosporins could be demonstrated (Figure 2).
Can one predict the sensitizing capacity and the expected incidence of allergic re-
actions in man from sensitizing experiments in guinea pigs or mice? There is, as yet, no
definite answer to the question. It is striking, however, that the poorer antibody re-
sponse to ampicillin in guinea pigs coincides with the fact that immediate-type reactions
to ampicillins are also much rarer in man than those to benzylpenicillin. As far as the
cephalosporins are concerned, the majority of studies performed thus far indicate that
the incidence of allergic reactions is low despite a dosage which is often higher than
used in penicillin therapy.
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Figure 2. Elicitation of PCA in guinea pigs sensitized with anti-CEFOX-BGG guinea pig antisemm by
means of 01 ^unol CEFOX-HSA (O O); 01 junol CEFOX-PLL (O O); 25 mg CEFOX
( • • ) ; 25 mg CETAX (A A); 10 mg CEPHOR ( • A); Ol ^mol CEPHOR-PLL
( • A); 0-1
 Fmol BPO-PLL (D D).
Allergenicity and cross-reactivity
The allergenicity, i.e. the capacity to elicit allergic reactions in already sensitized in-
dividuals and the cross-reactivity of a new cephalosporin are obviously of interest in
order to assess the risks of its potential use in a population which has been treated for
many years by penicillins or other cephalosporins. It is generally estimated that 3 to 5 %
of the individuals in industrialized countries are allergic to penicillins.
A first indication about the cross-reactivity and potential allergenicity of the new
cephalosporins cefotaxime and cefuroxime may be gained from studying the cross-
reactivity among antibodies raised in rodents by the corresponding cephalosporin- or
penicilloyl-protein conjugates. In guinea pigs with very high titres of antibodies raised
by cefuroxime-protein conjugates, there was practically no reaction with benzylpenicil-
lin and benzylpenicilloyl-protein antigens (Table III). Even with other cephalosporins
such as cephaloridine, cephalothin and cephalexin, only a very low grade of cross-
reactivity was observed suggesting that the bulk of the antibodies raised by cefur-
oxime-protein conjugates is directed against the side-chain and not against the entire
cephalosporoyl moiety. The observation that cefotaxime is definitely cross-reacting with
anti-bodies raised against cefuroxime would also fit into this picture since the respective
Rt side-chains of the two antibiotics share at least one structural element.
The antibody response obtained in guinea pigs against a cefotaxime-HSA conjugate
has not yet reached full strength. Nevertheless it is obvious that at least a weak cross-
reaction in PCA with CEFOX-PLL is elicitable; on the other hand the lack of cross-
reactivity with BPO-PLL is already apparent (Table IV).
The almost complete absence of cross-reactivity in human immediate-type allergy
was confirmed by studies on the IgE penicilloyl-specific antibodies of patients allergic
to penicillin. Among 22 individuals showing high levels of BPO-specific IgE antibodies
demonstrated by the RAST test, no IgE antibodies against the cefuroxime group were
detected (Table V). The same result is obtained from RAST inhibition experiments
where BPO-specific RAST binding can virtually not be inhibited by cefotaxime or
cefuroxime (Figure 3).
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Figure 3. Inhibition of RAST (BPO-specific human IgE-binding to BPO-HSA-sepharose) by penicillin
and cephalosporin haptens including CETAX (D • ) ; CEFOX ( • • ) ; BPN (O O);
BPO-FLYS ( • • ) .
Table HI. Elicitation of PCA reactions by ccphalosporins with various antisera induced by BPO-
BGG and CEFOX-BGG
Antiserum used for PCA Elicitor Result*
Guinea pig anti-CEFOX-BGG
(immuniz. in A1(OH)3)
Guinea pig anti-BPO-BGG
(immuniz. in A1(OH)3)
Guinea pig anti-BPO-BGG
(immuniz. in CFA)
Rabbit anti-BPO-BGG
(immuniz. in CFA)
CEFOX-HSA
CEFOX-PLL
CEFOX
CEPHOR-PLL
CEPHOR
CEPHALOT
CEPHALEX
CETAX
BPO-PLL
BPO-PLL
CEFOX-PLL
CEFOX
CEPHOR-PLL
CEPHOR
CEPHALOT
CEPHALEX
CETAX
CEFOX
CEPHOR
CETAX
CEFOX
CEPHOR
CETAX
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
: 10 000)
: 10 000)
:200)
:400)
:10)
:5)
:5)
:400)
:10)
: 10000)
:100)
:5)
:200)
:5)
:5)
:5)
:5)
:5)
:5)
:5)
:5)
:5)
:5)
•In ( ), end point PCA titre or for negatives, lowest serum dilution tested.
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TaMe IV. Evaluation by PCA of CETAX-sensitized guinea pigs*
Elicitor Dose Fraction of animals affording positive sera at
1:10 1:100 1:1000
CETAX-PLL 01 /imol
CEFOX-PLL 0-1 /imol
BPO-PLL 01 /imol
CETAX 1 mg
CETAX 0-1 mg
CEFOX 1 mg
8/8
1/8
0/8
2/8
1/8
2/8
6/8
ND
0/8
ND
ND
ND
4/8
ND
0/8
ND
ND
ND
•Eight guinea pigs immunized with 1 £ig CETAX-HSA in AJ(OH)3; PCA in guinea pigs with antisera from
day 90.
These results suggest that the penicillin- and cephalosporin-based haptenic structures
do not share structural moieties of sufficient immunochemical importance to form a
basis for IgE cross-reactivity. Indeed, reports of immediate-type reactions to cephalo-
sporins in penicillin-allergic patients are rather rare (Scholand, Tennenbaum & Cerilli,
1968) and seem to involve mainly cephalosporins with the thiophene side-chain such as
Table V. Rast test with BPO and CEFOX in 22 patients allergic to penicillin
Penicillin-allergic
patients:
Normal sera:
Buffer control;
Patient serum
no.
56
59
104
105
122
124
125
126
137
139
141
4
9
34
49
65
70
72
46
47
48
88
OP
2430
2024
2490
—
Labelled a-IgE (cts/min) bound to
BPO-HSA-Sepharose
10 691
11882
6142
804
11890
32 651
4 298
2 528
16190
7 920
4 950
10 910
24 720
5 610
11875
7 256
13 910
9 225
29 017
20 788
25 311
39 610
460
328
372
398
619
CEFOX-HSA-
Sepharose*
400
486
327
314
332
347
236
196
408
365
708
443
471
353
288
395
303
251
493
345
439
607
253
357
307
263
163
•Since we do not possess serum from a patient clinically sensitive to CEFOX as positive control, the
suitability of the CEFOX-HSA-Sepharoic immunosorbent was checked from its ability to adsorb guinea pig
anti-CEFOX antibodies.
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cephalothin. Since the thiophene ring (Pressman & Grossberg, 1968) is immunochemi-
cally and sterically very similar to the benzene side-chain of benzylpenicillin, and other
closely related penicillins, the observed cross-reactions may be mainly due to side-chain
similarity.
From our study on the specificity of antibodies raised in guinea pigs and man one
would be tempted to predict that no cross-reactivity is to be expected between penicil-
lins and cephalosporins provided the side-chains were sufficiently different in structure.
This conclusion, however, has to be modified when considering the results of lym-
phocyte culture experiments performed with lymphocytes from penicillin-sensitized
patients (Table VI). In that case, it is obvious that lymphocytes are stimulated to pro-
liferate not only by penicillins but also by most of the cephalosporins. Indeed, both
Table VI. Lymphocyte reactivity (stimulation index) of patients allergic to penicillin
Patient
no.
1089
1098
1097
1101
1100
1103
1110
1111
1096*
*Non-allergic
BPN
500
17-5
22-8
113
97-6
210-5
20-3
3-6
34-7
11
patient.
AMPIC
500
27-7
15-5
30
420
56-2
51
4-8
18-3
1-2
CEFOX
100
2-4
4-6
21
5-7
8-6
0-5
3-8
9-7
1-4
CETAX
200
1-9
7-7
2-5
14-3
7-0
0-5
41
13-4
1-6
CEPHALOT
100
3-4
1-6
2-3
13-6
160
0-2
6-4
8-6
1-5
CEPHALEX
10
0-9
1-5
1-4
11
0-8
1-0
11
2-6
0-6
CEPHOR
20 /ig/ml
2-3
2-1
1-2
10-4
22-4
0-8
3-6
6-8
1-0
cefotaxime and cefuroxime appeared to stimulate, although to a lesser extent, lym-
phocytes from patients having undergone clinical allergic reactions to benzylpenicillin
or to one of the semisynthetic penicillins. Accordingly, if immediate-type reactions in-
volving antibodies, and especially IgE antibodies, will probably be very rare with cefo-
taxime and cefuroxime in a population of penicillin-sensitized patients, cross-allergic
manifestations based on cellular reactivity such as generalized maculo-papular exan-
thema or fever may be expected in a sizeable proportion of cases.
In summary, cefotaxime and cefuroxime appear, at least under experimental con-
ditions, to be less immunogenic than benzylpenicillin and semisynthetic penicillins and
to be less prone to produce antibody of the IgE type. Cross-reactions with rodent or
human IgE antibodies induced by benzylpenicillin appear to be minimal. Cross-
reactions may be expected, however, between cephalosporins and penicillins carrying
similar side-chains. Some cross-reactivity at the level of the nucleus on the other hand
has been observed with penicillin-sensitized lymphocytes. Accordingly, some cross-
reactivity at the level of cell-mediated allergic reactions may be expected. In comparison
to some other cephalosporins, cefotaxime appears to be less toxic for the lymphoid cells
and macrophages required for immune defences.
References
Dewdney, J. M. Immunology of the antibiotics. In The Antigens, Vol. IV (Sela, M., Ed.) Academic
PTCSS, New York (1977), pp. 74-245.
168 A. L. de Week and C H. Schneider
Hamilton-Miller, J. M. T., Newton, G. G. F. & Abraham, E. P. Products of aminolysis and
enzymic hydrolysis of the cephalosporins. Biochemical Journal 116: 371-84 (1970).
Pressman, D. & Grossberg, A. L. The Structural Basis of Antibody Specificity. Benjamin, New
York (1968), pp. 50-2.
Stemberger, H. & Wiedermann, C. Untersuchungen uber die Bindung von Cephalosporin-C-
Antibiotica an Eiweiss. Zeitschrift lmmunitatsforschung und experimentellt Therapie 140:
43-9 (1970).
Scholand, J. F., Tennenbaum, J. I. & Cerilli, G. J. Anaphylaxis to cephalothin in a patient allergic
to penicillin. Journal of the American Medical Association 206: 130-3 (1968).
